Alpha-synuclein and Parkinson's disease

Cellular and Molecular Life Sciences

Volumn 57, Issue 13-14, 2000, Pages 1894-1908

  Lucking C B ^a   Brice, A ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Aggregation; Genetics; Inclusions; Neurodegeneration; Parkinson's disease; T oxicity; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID;

CELL SURVIVAL; DEGENERATIVE DISEASE; DOPAMINERGIC TRANSMISSION; GENE MUTATION; HUMAN; LEWY BODY; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; PARKINSON DISEASE; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034489853     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000671     Document Type: Review

References (141)

1. Prevalence of parkinsonism and Parkinson's disease in Europe: The EU-ROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease
2. Ageing and Parkinson's disease: Substantia nigra regional selectivity
3. Genetic aspects of Parkinson's disease
4. Genetics of Parkinson's disease
5. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins
6. Clinical genetic analysis of Parkinson's disease in the Contursi kindred
7. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27
8. High-resolution mapping of SNCA encoding alphasynuclein, the non-A beta component of Aizheimer's disease amyloid precursor, to human chromosome 4q21.3 → q22 by fluorescence in situ hybridization
9. Assignment of human alpha-synuciein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35
10. The NACP/synuclein gene: Chromosomal assignment and screening for alterations in Alzheimer disease
11. The human NACP/alpha-synuclein gene: Chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis
12. Identification, localization and characterization of the human gamma-synuclein gene
13. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal
14. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Aizheimer disease
15. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch
16. The rat brain synucleins: Family of proteins transiently associated with neuronal membrane
17. Identification of two distinct synucleins from human brain
18. The precursor protein of non-A beta component of Aizheimer's disease amyloid is a presynaptic protein of the central nervous system
19. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid
20. Purification and characterization of a novel brain-specific 14-kDa protein
21. Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization
22. A new brain-specific 14-kDa protein is a phosphoprotein: Its complete amino acid sequence and evidence for phosphorylation
23. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system
24. Peripheral nervous system-specific genes identified by subtractive cDNA cloning
25. Persyn, a member of the synuclein family, influences neurofilament network integrity
26. Identification of a breast cancer-specific gene. BCSG1, by direct differential cDNA sequencing
27. Stimulation of breast cancer invasion and metastasis by synuclein gamma
28. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded
29. Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil
30. Delayed localization of synelfin (synuclein NACP) to presynaptic terminals in cultured rat hippocampal neurons
31. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
32. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes
33. Characterization of α-synuclein/NACP's lipid binding domain
34. Membrane association and protein conformation of alpha-synuclein in intact neurons: Effect of Parkinson's disease-linked mutations
35. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system
36. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein
37. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins
38. Alpha-synuclein shares physical and functional homology with -14-3-3 proteins
39. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions
40. Synphilin-1 is present in Lewy bodies in Parkinson's disease
41. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
42. Microtubule-associated protein tau: A component of Alzheimer paired helical filaments
43. Alpha-synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356
44. Binding of Abeta to alpha- and beta-synucleins: Identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC
45. NACP, the precursor protein of the nonamyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation
46. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding
47. Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex
48. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury
49. Regulation of synuclein-1 in response to NGF treatment in rat pheochromocytoma PC12 cells
50. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development
51. Neural expression profile of alpha-synuclein in developing human cortex
52. Role of phospholipase D activation in nervous system physiology and pathophysiology
53. Mice lacking alphasynuclein display functional deficits in the nigrostriatal dopamine system
54. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
55. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease
56. The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease
57. Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine
58. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
59. Mutation in the alpha synuclein gene identified in families with Parkinson's disease
60. Genetics of Parkinson's disease
61. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
62. Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients
63. Absence of the G209A mutation in the alpha-synuclein gene in British families with Parkinson's disease
64. Low frequency of alpha-synuclein mutations in familial Parkinson's disease
65. Lack of mutation G209A in the alpha-synuclein gene in French patients with familial and sporadic Parkinson's disease
66. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases
67. The G209A mutation in the alphasynuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations
68. Analysis of the alpha-synuclein G209A mutation in familial Parkinson's disease
69. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease
70. Alphasynuclein gene and Parkinson's disease
71. Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations
72. Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson's disease
73. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease
74. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease
75. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease
76. Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease
77. No pathogenic mutations in the beta-synuclein gene in Parkinson's disease
78. No pathogenic mutations in the persyn gene in Parkinson's disease
79. Mutations in the gene encoding human persyn are not associated with amyotrophic lateral sclerosis or familial Parkinson's disease
80. Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism
81. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: Incomplete penetrance?
82. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein
83. Mutation screening in the coding region of α-syuclein gene in multiple system atrophy (MSA)
84. Alpha-synuclein in Lewy bodies
85. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
86. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies
87. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease
88. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
89. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited: NAC and alpha-synuclein are not associated with Abeta amyloid
90. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
91. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity
92. Numerous and widespread alphasynuclein-negative Lewy bodies in an asymptomatic patient
93. Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein
94. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains
95. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic
96. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores
97. Alpha synuclein in neurodegenerative disorders: Murderer or accomplice?
98. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders
99. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy, and Shy-Drager syndrome)
100. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
101. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies
102. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy
103. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy
104. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components
105. Widespread alterations of alpha-synuclein in multiple system atrophy
106. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders
107. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology
108. Human recombinant NACP/alphasynuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease
109. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro
110. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease
111. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation
112. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
113. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
114. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: Is NAC a common trigger or target in neurodegenerative disease?
115. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments
116. Alpha-synuclein fibrillogenesis is nucleation-dependent: Implications for the pathogenesis of Parkinson's disease
117. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alphasynuclein protein implicated in Parkinson's disease
118. Synthetic filaments assembled from C-terminally truncated alpha-synuclein
119. α-Synuclein and the ubiquitin-proteasome pathway
120. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasoreal degradation in HEK293 and neuronal cells
121. Degradation of alpha-synuclein by proteasome
122. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
123. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
124. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia
125. Iron induced oxidative stress and mitochondrial dysfunction relevance to Parkinson's disease
126. Free radicals and mitochondrial dysfunction in Parkinson's disease
127. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
128. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro
129. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease
130. Copper (II)-induced self-oligomerization of alphasynuclein
131. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid
132. Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35)
133. Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide
134. Isoform-specific binding of human apolipoprotein E to the non-amyloid beta component of Alzheimer's disease amyloid
135. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype
136. Overexpression of mutant human α-synuclein (A53T) causes dopamine neuron death in rat primary culture and in rat mesencephalon-derived cell line (IRB3AN27)
137. Mutated human α-synuclein increases the vulnerability of neuronal cells to oxidative stress
138. α-Synuclein attenuates ERK/ELK signalling
139. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
140. A Drosophila model of Parkinson's disease
141. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease